Structured evidence table for Ginkgo Focus Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Ginkgo Focus Randomized Trial | Conclusion Current RCT evidence shows inconsistent and limited findings, and no firm conclusions can be drawn about whether any OTC therapy provides symptomatic benefit. | 1 | Menon R (2026) | Effectiveness of Over-The-Counter Treatments for Tinnitus Symptom Relief: A Systematic Review. |
| Ginkgo Focus Randomized Trial | Level of evidence 1 (Systematic review of RCTs with low-moderate heterogeneity). | 1 | Menon R (2026) | Effectiveness of Over-The-Counter Treatments for Tinnitus Symptom Relief: A Systematic Review. |
| Ginkgo Focus Randomized Trial | Objective To review the effectiveness of over-the-counter (OTC) treatments in reducing tinnitus symptom severity as measured by the Tinnitus Handicap Inventory (THI) in randomized controlled trials. | 1 | Menon R (2026) | Effectiveness of Over-The-Counter Treatments for Tinnitus Symptom Relief: A Systematic Review. |
| Ginkgo Focus Randomized Trial | Methods A comprehensive search was conducted in PubMed, Embase, Cochrane CENTRAL, ClinicalTrials.gov, and WHO ICTRP through March 2025. | 1 | Menon R (2026) | Effectiveness of Over-The-Counter Treatments for Tinnitus Symptom Relief: A Systematic Review. |
| Ginkgo Focus Randomized Trial | In addition, an overview of systematic reviews synthesized the broader EGb 761 evidence base across indications and highlighted that conclusions require caution given the methodological limitations of many reviews []. | 3 | Yang YoungSoon (2026) | Ginkgo Biloba for Alzheimer’s Disease: From Mixed Dementia Trials to Biomarker-Confirmed Mild Cognitive Impairment—What Have We Learned over Two Decades, and Is There Finally a Bit of Hope? |
| Ginkgo Focus Randomized Trial | Real-world observational analyses have also reported associations between prescriptions of Ginkgo leaf extract and reduced risk of dementia severity progression, albeit with the inherent limitations of non-randomized designs []. | 3 | Yang YoungSoon (2026) | Ginkgo Biloba for Alzheimer’s Disease: From Mixed Dementia Trials to Biomarker-Confirmed Mild Cognitive Impairment—What Have We Learned over Two Decades, and Is There Finally a Bit of Hope? |
| Ginkgo Focus Randomized Trial | Accordingly, this review revisits the historical evidence base with explicit attention to heterogeneity and methodological design, and then examines biomarker-confirmed AD-spectrum studies as a potential pivot point. | 3 | Yang YoungSoon (2026) | Ginkgo Biloba for Alzheimer’s Disease: From Mixed Dementia Trials to Biomarker-Confirmed Mild Cognitive Impairment—What Have We Learned over Two Decades, and Is There Finally a Bit of Hope? |
| Ginkgo Focus Randomized Trial | 1 2 Alzheimer’s disease (AD) remains the most common cause of dementia and continues to impose a major burden on patients, caregivers, and healthcare systems []. | 3 | Yang YoungSoon (2026) | Ginkgo Biloba for Alzheimer’s Disease: From Mixed Dementia Trials to Biomarker-Confirmed Mild Cognitive Impairment—What Have We Learned over Two Decades, and Is There Finally a Bit of Hope? |
Source documents